Evidence map›Paper›PMID 41473019›Full record

ArticleACS applied electronic materials2025

Development of a Piezoelectric Immunosensor to Rapidly Measure Prohibitin‑1 as a Prognostic Biomarker for Sepsis and Other Serious Infectious Diseases.

Eman S Kamel, Yusra Rahman, Jolonda C Mahoney, Ethan J Anderson, Reza Nejadnik

Abstract read
In one paragraph

Article in ACS applied electronic materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eman S KamelDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.
Yusra RahmanDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.
Jolonda C MahoneyDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.
Ethan J AndersonDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.
Reza NejadnikDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.ORCID https://orcid.org/0000-0003-3370-6491

Funding

Determinants of cardioprotection by circulating prohibitin-1 during sepsisR01HL167087 · NHLBI · UNIVERSITY OF IOWA · PI Ethan John Anderson · 2023 to 2026
$1.8M
NHLBI NIH HHS R01 HL167087
6 · The paper itself

Abstract

Sepsis is a life-threatening condition and the leading cause of mortality worldwide, particularly when an affected patient develops multiple organ dysfunction syndrome (MODS), a serious complication defined as progressive and potentially irreversible dysfunction in two or more organ systems. Clinical and experimental studies strongly suggest that patient outcomes with sepsis would improve if the risk for MODS and mortality could be identified in the first few hours after the onset of symptoms. We present an approach leveraging quartz crystal microbalance with dissipation monitoring (QCM-D) technology for rapid (∼30 min) detection of prohibitin-1 (PHB1), a protein with pleiotropic biological function that dramatically increases in blood during the acute phase of an infection. The feasibility of detection and reproducible quantification of recombinant PHB1 in physiological buffered conditions is described. Sensitivity and detection limit for the third overtone (12.19 Hz μg

Indexed as

biomarker detectionELISAfrequency shiftimmunosensorMODSprohibitin-1quartz crystal microbalancesepsis

Identifiers

PMID41473019
PMCPMC12746439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.